Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F19%3A43920834" target="_blank" >RIV/00023752:_____/19:43920834 - isvavai.cz</a>
Alternative codes found
RIV/68081731:_____/19:00508401 RIV/00216224:14110/19:00109798
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0028390818308761#" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0028390818308761#</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1142/S0129065719500035" target="_blank" >10.1142/S0129065719500035</a>
Alternative languages
Result language
angličtina
Original language name
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia
Original language description
In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the anti mitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively. At the molecular level, an increased cannabinoid receptor type-1 (CB1) mRNA and protein expression, which might be due to reduction in DNA methylation at the gene promoter in the prefrontal cortex (PFC), coincided with deficits in the social interaction test and in the novel object recognition test in MAM rats. Both the schizophrenia-like phenotype and altered transcriptional regulation of CB1 receptors were reversed by peripubertal treatment (from PND 19 to PND 39) with the non-psychotropic phytocannabinoid cannabidiol (30 mg/kg/day), or, in part, by treatment with the cannabinoid CB1 receptor antagonist/inverse agonist AM251 (0.5 mg/kg/day), but not with haloperidol (0.6 mg/kg/day). These results suggest that early treatment with cannabidiol may prevent both the appearance of schizophrenia-like deficits as well as CB1 alterations in the PFC at adulthood, supporting that peripubertal cannabidiol treatment might be protective against MAM insult.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neuropharmacology
ISSN
0028-3908
e-ISSN
—
Volume of the periodical
146
Issue of the periodical within the volume
March
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
212-221
UT code for WoS article
000457663900021
EID of the result in the Scopus database
2-s2.0-85058120018